背景下消化道出血栓塞 Embolisation for lower GI bleeding 所以弹簧栓子的应用要超选择,所谓How distal does LGIB embolization need to be?
- <三个直动脉没有危险 3 or fewer vasa recta: not risky
- ≥ 4个直动脉有危险 4 or more vasa recta: risky
那么,液体栓塞剂在下消化道出血栓塞中的角色是什么呢? 1. 什么时候和如何在下消化道出血的情况下使用液体栓塞剂栓塞 2. 下消化道出血液体栓塞剂的优缺点 3. 下消化道出血液体栓塞剂的结果和并发症 液体包括哪些?NBCA:Acrylic glues: n-butyl cyanoacrylates = N-butyl 2-cyanoacrylate Onyx:Onyx Liquid Embolic System
- Polymere: Ethylene-vinyl
- alcohol copolymer (EVOH)
- Solvent: Dimethyl sulfoxide (DMSO) solvent
- Radiopacifying: Micronized tantalum powder
|
病例二 Onyx
下消化道出血栓塞液体栓塞剂如何用?
- 标准4或5Fr导管 Standard 4 or 5-Fr catheter
- 微导管选择到尽可能的远端 Microcatheter as distal as possible
- 注射Onyx之前用5%葡萄糖水或MDSO冲洗 Previous flushing with G5% or DMSO
- 1-3ml带锁扣的注射器注射 1 or 3 mL luer-lock syringe for injection
- 用碘油调整聚合的速率 Use Lipiodol to modulate the rate of glue polymerisation
- 在透视下缓慢注射Slow and regular injection under strict fluoroscopic control
- 快速去除微导管 Prompt removal of microcatheter with glue
- 血管近端对照造影 Final proximal control angiography
病例三:Front and back door embolization with Onyx
病例四:Also possible with Glubran2 (< 4 vasa recta)
液体胶的缺点(Drawback)
学习曲线 Learning curve:
- 稀释 Dilution (glue ++)
- 理想注射 Optimal injection
- 并发症预防 Prevention of complications:
+ 导管粘连 Sticking catheter:
Glue >> Onyx
+ Ischemic risk:
Glue = Onyx
+ Non target occlusion:
Glue > Onyx
强力胶水
消化道出血最常见应用微弹簧栓子、500-700μmPVA,明胶海绵粉,但在严重出血的情况下,胶或Onyx应该考虑,但是否增加肠缺血是值得进一步探讨的事。总的来说下消化道出血栓塞严重的肠缺血需要外科的大约2%。
Outcomes of LGIB embolization with ONYX
39例下消化道出血没有严重肠缺血
201例下消化道出血栓塞的病人,4例肠缺血需要外科手术,=1.99%
Cavity filling Controlled sandwich (Onyx+++)
Onyx
强力胶水
液体栓塞剂的结果
消化道出血最常见应用微弹簧栓子、500-700μmPVA,明胶海绵粉,但在严重出血的情况下,胶或Onyx应该考虑,但是否增加肠缺血是值得进一步探讨的事。总的来说下消化道出血栓塞严重的肠缺血需要外科的大约2%。
Outcomes of LGIB embolization with ONYX
UGIB | LGIB | Technical success | Clinical success | Re bleeding | Major complications | 30-day mortality | |
Lenhart Eur Radiol 2010 | 10 | 6 | 100% | 81% | 6.2% | 0% | 12.5% |
Urbano JVIR 2014 | 0 | 31 | 93.5% | 96.7% | 10% | 0% | 6.4% |
Sun Indian J Cancer 2015 | 7 | 2 | 100% | 100% | 0% | 0% | 0% |
UGIB | LGIB | Technical success | Clinical success | Re bleeding | Major complications | 30-day mortality | |
Frodsham JVIR 2009 (T) |
0 | 14 | 100% |
79% |
21% | 0% | 7.1% |
Huang JVIR 2011 (H) |
0 | 27 | 100% | 67% | 14.8% | 0% | 33% |
Yata JVIR 2013 (H) |
16 | 23 | 100% | 95% | 5% | 8.1% | 21.6% |
Hur JVIR 2014 (?) |
0 | 84 | 100% | 75.3% | 15.2% | 4.8% | 26.2% |
Koo AJR 2015 (H) |
72 | 30 | 100% | 76.5% | 15.7% | 1.9% | 8.8% |
Kodani JVIR 2016 (?) |
0 | 16 | 100% | 93.8% | 6.2% | 12.5% | 0% |
Zhao Gastr Res 2016 (?) |
0 | 7 | 100% | 85.8% | 14.2% | 0% | 0% |
201例下消化道出血栓塞的病人,4例肠缺血需要外科手术,=1.99%
Onyx